The EMA CHMP has recommended that the use of Tecovirimat SIGA be restricted in the treatment of mpox (monkey pox). This decision is based on a review of the available data. The reason for the restriction is a change in the assessment of the ratio of benefits and risks of the drug in the context of the current epidemiological situation. The recommendation refers only to the treatment of mpox and does not affect other indications, if any. EMA will continue to monitor the situation and will reassess its position if necessary. The exact details of the restriction will be published in the updated product information.